A new market report projects the respiratory disease vaccine market will hit $98.41 billion by 2035, growing at a CAGR of 4.12%. North America currently holds the largest share, but Asia-Pacific is expected to see the fastest growth over the next decade. Key drivers include the shift toward mRNA technology and new RSV vaccines. The report highlights recent developments like Novavax collaborating with Sanofi on flu vaccines and Merck getting FDA approval for their infant RSV antibody. Moderna is also running trials for a single shot targeting multiple respiratory viruses. Major players mentioned include Pfizer, GSK, and AstraZeneca as governments continue to fund immunization programs.